Eli Lilly & Co./Daiichi Sankyo Co. Ltd.were not able to show Effient (prasugrel) was superior to Bristol-Myers Squibb Co./Sanofi’s Plavix (clopidogrel) in a head to head study, but the partners have gained evidence that the rates of major bleeding were similar – an outcome that could be used in Effient’s favor.
The TRILOGY ACS study was published in the New England Journal of Medicine on Aug. 26, in conjunction with its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?